Jamshedpur Reporter

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs, and Companies

 Breaking News
  • No posts were found

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs, and Companies

June 17
18:50 2024
Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs, and Companies

DelveInsight’s, “Bile Duct Cancer (Cholangiocarcinoma) Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape. It covers the Bile Duct Cancer (Cholangiocarcinoma) pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bile Duct Cancer (Cholangiocarcinoma) therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Bile Duct Cancer (Cholangiocarcinoma) Research. Learn more about our innovative pipeline today! @ Bile Duct Cancer (Cholangiocarcinoma) Pipeline Outlook

 

Key Takeaways from the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report

  • June 2024:- TransThera Sciences (Nanjing) Inc.- This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma.
  • June 2024:- Australasian Gastro-Intestinal Trials Group- The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.
  • June 2024:- Ze-yang Ding, MD– This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.
  • June 2024:- M.D. Anderson Cancer Center– Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion. To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
  • June 2024:- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest– The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled.
  • DelveInsight’s Bile Duct Cancer (Cholangiocarcinoma) pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Bile Duct Cancer (Cholangiocarcinoma) treatment.
  • The leading Bile Duct Cancer (Cholangiocarcinoma) Companies such as Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
  • Promising Bile Duct Cancer (Cholangiocarcinoma) Therapies such as GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.

 

Stay informed about the cutting-edge advancements in Bile Duct Cancer (Cholangiocarcinoma) treatments. Download for updates and be a part of the revolution in cancer care @ Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Assessment

 

Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs Profile

 

  • TT-00420: TransThera Biosciences

TT-00420 is an innovative, global phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of TT-00420 to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, TT-00420 was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.

  • VG161: Virogin Biotech

VG161, Virogin’s pioneering oncolytic virus built on the company’s proprietary SynerlyticTM Platform, is an attenuated herpes simplex virus type 1 (HSV-1) armed with multiple payloads of IL12 & IL15/IL15Ra and a unique PD-L1 blocking peptide. The neurovirulence of wild-type HSV-1 is mitigated by the deletion of ICP 34.5 gene. These payloads can synergistically stimulate both innate and adaptive anti-tumor immunity in the tumor microenvironment. VG161 has been confirmed to be safe and effective in many tumor xenograft mouse models and in GLP toxicity studies preclinically. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cholangiocarcinoma.

  • NXP800: Nuvectis Pharma

NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator. NXP800 is also being evaluated in an investigator-initiated study conducted in collaboration with the Mayo Clinic for the treatment of cholangiocarcinoma, an indication for which the FDA granted NXP800 Orphan Drug Designation. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA. NXP800 completed a Phase 1a dose-escalation study in the first half of 2023. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Cholangiocarcinoma.

 

Learn more about Bile Duct Cancer (Cholangiocarcinoma) Drugs opportunities in our groundbreaking Bile Duct Cancer (Cholangiocarcinoma) Research and development projects @ Bile Duct Cancer (Cholangiocarcinoma) Unmet Needs

 

Bile Duct Cancer (Cholangiocarcinoma) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Bile Duct Cancer (Cholangiocarcinoma) Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Bile Duct Cancer (Cholangiocarcinoma) treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Bile Duct Cancer (Cholangiocarcinoma) Market Drivers and Barriers, and Future Perspectives

 

Scope of the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report

  • Coverage- Global
  • Bile Duct Cancer (Cholangiocarcinoma) Companies- Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
  • Bile Duct Cancer (Cholangiocarcinoma) Therapies- GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
  • Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Bile Duct Cancer (Cholangiocarcinoma) pipeline on our website @ Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Bile Duct Cancer (Cholangiocarcinoma): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Bile Duct Cancer (Cholangiocarcinoma)– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. TT-00420: TransThera Biosciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. VG161: Virogin Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. NXP800: Nuvectis Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Bile Duct Cancer (Cholangiocarcinoma) Key Companies
  21. Bile Duct Cancer (Cholangiocarcinoma) Key Products
  22. Bile Duct Cancer (Cholangiocarcinoma)- Unmet Needs
  23. Bile Duct Cancer (Cholangiocarcinoma)- Market Drivers and Barriers
  24. Bile Duct Cancer (Cholangiocarcinoma)- Future Perspectives and Conclusion
  25. Bile Duct Cancer (Cholangiocarcinoma) Analyst Views
  26. Bile Duct Cancer (Cholangiocarcinoma) Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/